Eosinophilic Annular Erythema- Successful Treatment with Dupilumab

Main Article Content

Alina G Zufall
University of Virginia
http://orcid.org/0000-0002-7622-2270
Rung-chi Li
University of Virginia

Barrett J Zlotoff
University of Virginia

Monica G Lawrence
University of Virginia

Richard H Flowers

Keywords

eosinophilic annular erythema, Dupilumab, biologic therapy, eosinophilic dermatosis

Abstract

Eosinophilic annular erythema (EAE) is a rare eosinophilic dermatosis with few documented cases in the literature. It is considered either a distinct entity or subtype of Well’s syndrome (eosinophilic cellulitis), but EAE, in contrast to Well’s syndrome, is characterized by a chronic course and resistance to treatment. Therapies with reported efficacy include anti-malarial medications, suplatast tosilate, and dapsone. We report the first adult case of EAE to respond to dupilumab, an IL-4 receptor antagonist, which targets the type 2 inflammatory response associated with tissue eosinophilia. 

References

1. El-Khalawany M, Al-Mutairi N, Sultan M, Shaaban D. Eosinophilic annular erythema is a peculiar subtype in the spectrum of Wells syndrome: a multicentre long-term follow-up study. J Eur Acad Dermatol Venereol. 2013;27(8):973-979. doi:10.1111/j.1468-3083.2012.04616.x

2. Kahofer P, Grabmaier E, Aberer E. Treatment of eosinophilic annular erythema with chloroquine. Acta Derm Venereol. 2000;80(1):70-71. doi:10.1080/000155500750012685

3. Nakazato S, Fujita Y, Shinkuma S, Nomura T, Shimizu H. Eosinophilic annular erythema is clinically characterized by central pigmentation reflecting basal melanosis: a clinicopathological study of 10 cases. J Eur Acad Dermatol Venereol. 2017;31(11):1916-1923. doi:10.1111/jdv.14350

4. Howes R, Girgis L, Kossard S. Eosinophilic annular erythema: a subset of Wells’ syndrome or a distinct entity? Australas J Dermatol. 2008;49(3):159-163. doi:10.1111/j.1440-0960.2008.00456.x

5. Kanameishi S, Goto K, Ogawa M, Fukumoto T, Tanabe H. Efficacy of suplatast tosilate in a case of recurrent eosinophilic annular erythema. Int J Dermatol. 2018;57(9):e66-e68. doi:10.1111/ijd.13973

6. Manriquez J, Berroeta-Mauriziano D, Andino-Navarrete R, Vera-Kellet C. Eosinophilic annular erythema: complete clinical response with dapsone. Int J Dermatol. 2015;54(4):e96-98. doi:10.1111/ijd.12736

7. Thomas L, Fatah S, Nagarajan S, Natarajan S. Eosinophilic annular erythema: successful response to ultraviolet B therapy. Clin Exp Dermatol. 2015;40(8):883-886. doi:10.1111/ced.12668

8. Gordon SC, Robinson SN, Abudu M, et al. Eosinophilic annular erythema treated with dupilumab. Pediatr Dermatol. 2018;35(4):e255-e256. doi:10.1111/pde.13533

9. Goldminz AM, Scheinman PL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther. 2018;31(6):e12701. doi:10.1111/dth.12701

10. Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol. 2018;154(10):1225-1226. doi:10.1001/jamadermatol.2018.2526

11. Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2019;155(1):118-120. doi:10.1001/jamadermatol.2018.3912

Article Sidebar

PDF
Published
May 8, 2020
DOI https://doi.org/10.25251/skin.4.3.10

Article Details

How to Cite
Zufall, A. G., Li, R.- chi, Zlotoff, B. J., Lawrence, M. G., & Flowers, R. H. (2020). Eosinophilic Annular Erythema- Successful Treatment with Dupilumab. SKIN The Journal of Cutaneous Medicine, 4(3), 268–271. https://doi.org/10.25251/skin.4.3.10
Issue
Vol. 4 No. 3 (2020)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.